Ameritas Advisory Services LLC Makes New Investment in Tempus AI, Inc. $TEM

Ameritas Advisory Services LLC acquired a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 10,450 shares of the company’s stock, valued at approximately $843,000.

Other large investors have also recently made changes to their positions in the company. AQR Capital Management LLC purchased a new position in Tempus AI during the 2nd quarter valued at approximately $54,020,000. Geode Capital Management LLC grew its holdings in shares of Tempus AI by 411.4% in the second quarter. Geode Capital Management LLC now owns 649,420 shares of the company’s stock valued at $41,264,000 after purchasing an additional 522,443 shares in the last quarter. Legal & General Group Plc raised its stake in Tempus AI by 24.4% during the second quarter. Legal & General Group Plc now owns 450,645 shares of the company’s stock valued at $28,634,000 after purchasing an additional 88,373 shares in the last quarter. Marex Group plc bought a new stake in shares of Tempus AI in the 2nd quarter worth about $26,620,000. Finally, Gilder Gagnon Howe & Co. LLC increased its position in shares of Tempus AI by 1,747.6% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 413,081 shares of the company’s stock valued at $26,247,000 after purchasing an additional 390,723 shares during the last quarter. 24.22% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Piper Sandler reduced their price objective on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. TD Cowen downgraded Tempus AI from a “buy” rating to a “hold” rating in a research report on Tuesday, October 21st. BTIG Research upped their price target on shares of Tempus AI from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. HC Wainwright reduced their price target on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Finally, Morgan Stanley boosted their price objective on shares of Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday, December 1st. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Tempus AI presently has a consensus rating of “Hold” and an average price target of $87.20.

Insider Activity

In other Tempus AI news, COO Ryan Fukushima sold 5,000 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $64.26, for a total transaction of $321,300.00. Following the completion of the sale, the chief operating officer directly owned 148,808 shares of the company’s stock, valued at approximately $9,562,402.08. This represents a 3.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO James William Rogers sold 19,966 shares of the firm’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $73.20, for a total transaction of $1,461,511.20. Following the completion of the sale, the chief financial officer owned 111,250 shares in the company, valued at $8,143,500. This represents a 15.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 761,582 shares of company stock worth $51,997,831 over the last ninety days. 26.27% of the stock is currently owned by corporate insiders.

Tempus AI Stock Up 2.3%

Tempus AI stock opened at $51.95 on Friday. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45. The firm has a market cap of $9.24 billion, a P/E ratio of -43.66 and a beta of 5.22. The business has a fifty day moving average of $64.22 and a two-hundred day moving average of $73.54. Tempus AI, Inc. has a twelve month low of $36.22 and a twelve month high of $104.32.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.